Kavenpreet Singh Bal

Kavenpreet Singh Bal

Auto-generated profile, based on publicly available information

Kavenpreet Singh Bal

Kaiser Permanente Bernard J Tyson School of Medicine, Pasadena, CA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
KYKevin Yen
Kevin Yen
SBSonali Belapurkar
Sonali Belapurkar
CPCassidy Puckett
Cassidy Puckett
NCNatalie S. Chen
Natalie S. Chen
LYLoren Yglecias
Loren Yglecias
JWJenise C. Wong
Jenise C. Wong
Background: Disparities in outcomes and technology use in children with Type 1 diabetes (T1D) from underresourced backgrounds are well documented. The feasibility of initiating automated insulin delivery (AID) soon after diagnosis of T1D is less certain in this population. This pilot study assessed the feasibility and acceptability of providing access to the Tandem Control‐IQ AID system to children with public insurance soon after T1D diagnosis. Methods: Publicly insured children aged 6–21 years of age within 3 months of T1D diagnosis were eligible for the study. Participants were randomized 2:1 to AID or usual care for 6 months. Continuous glucose monitoring data were collected at baseline, 3 months, and 6 months. Caregivers and youth completed closing surveys and participated in focus group interviews to assess safety and user experience. Results: Nineteen youth were enrolled, with thirteen in the intervention and six in the control group. The mean age was 11.5 ± 2.3 years, 47% were female, and 89% were from underrepresented racial or ethnic groups. A larger proportion of the AID group compared to the control group achieved the American Diabetes Association benchmark of > 70% time in range (50% vs. 0% of participants at 3 months; 37% vs. 0% of participants at 6 months; not statistically significant). All caregivers and 69% of youth in the AID group reported satisfaction, and 85% of youth continued using AID 6 months after the completion of the study. Focus groups showed favorable experiences with AID use. Conclusion: Early initiation of AID is feasible and acceptable in youth with recently diagnosed T1D from underresourced populations who historically experience lower technology adoption and less optimal glycemic outcomes. Diabetes clinicians should consider providing tailored support and dedicated resources to families early in diagnosis with T1D to promote AID initiation and continued use.

13 October 2026 in JACC: Advances
Verified
Journal Article
Open access
KBKavenpreet S. Bal
Kavenpreet S. Bal
MRMikaila P. Reyes
Mikaila P. Reyes
AKAlka M. Kanaya
Alka M. Kanaya
PTPam Taub
Pam Taub
MTMichael Y. Tsai
Michael Y. Tsai
HBHarpreet S. Bhatia
Harpreet S. Bhatia
South Asian individuals have a high prevalence of elevated lipoprotein(a) [Lp(a)], but little is known about the variation between disaggregated South Asian subgroups. The authors aimed to evaluate Lp(a) levels, nongenetic influences, and the association with incident atherosclerotic cardiovascular disease (ASCVD) in South Asian populations using data from the Meditators of Atherosclerosis in South Asians Living in America (MASALA) and the UK Biobank (UKB) studies. Lp(a) levels were assessed by South Asian country of origin and by state among Indian-origin participants. The association between nongenetic factors and Lp(a) levels was evaluated in multivariable linear regression models. Cox proportional hazards models evaluated the association between Lp(a) and ASCVD events in UKB participants. Among 2,074 MASALA participants born in the South Asian subcontinent (mean age: 56.7 ± 9.6 years), median [Q1-Q3] Lp(a) was 20.7 [10.5-43.0] mg/dL with significant variation by country of origin (P = 0.035). Median Lp(a) was 23 [11-48], 19 [10-37], 22 [11-47], and 17 [10-34] mg/dL in participants from Bangladesh, India, Pakistan, and Sri Lanka, respectively. Vegetarian diet, statin use, postmenopausal status, and fewer years in the United States were associated with higher Lp(a) levels while alcohol consumption was associated with lower Lp(a) levels. However, these associations were all very modest. Among 6,845 UKB participants (mean age: 55.1 ± 8.7 years; median Lp(a): 31 [13-65] nmol/L), the associations between Lp(a) and ASCVD did not vary by country of origin or South Asian ethnicity (P interaction > 0.05). There is modest variation in Lp(a) levels, but no difference in the association between Lp(a) and ASCVD outcomes, across South Asian subgroups.

14 March 2025 in The Permanente Journal
Verified
Journal Article
Open access
KBKavenpreet Singh Bal
Kavenpreet Singh Bal
PAPriyanka Achalu
Priyanka Achalu
MOMichael O Okene
Michael O Okene
AKAaron Krug
Aaron Krug
THTung-Chin Hsieh
Tung-Chin Hsieh
HMHossein Mirheydar
Hossein Mirheydar
Peyronie's disease (PD) is a progressive fibrotic disorder of the penis that can induce pain and erectile dysfunction and has various treatment modalities, including surgical, pharmaceutical, and Clostridium histolyticum injection therapies. The authors used electronic medical records from Kaiser Permanente Southern California, an integrated health care system that consists of 15 medical centers, and identified patients diagnosed with stable PD without concomitant erectile dysfunction from January 1, 2004, to December 31, 2020. Baseline characteristics between surgical and injection groups were compared using Chi-squared and Kruskal-Wallis tests. Multivariable logistic regression with adjustment of confounders was implemented to identify which variables may influence whether patients received injection or surgical therapy. A total of 11,706 patients with PD were identified. The rate of new PD diagnosis per 100,000 patients increased by 0.37 every year, P < .05. The incident rate (per 1000 eligible patients) of surgical management declined on average by 0.40 each year (P < .001), although there was an increase rate of 1.19 for injection therapy (P < .001). On multivariable modeling, patients 45-54 years of age were more likely to receive injection therapy as the primary treatment for PD (adjusted odds ratio = 2.77; P = .002; confidence interval = 1.34-5.73). This study illustrates that pentoxifylline is now more frequently used than colchicine and vitamin E as oral treatments for PD, while collagenase C. histolyticum injection therapy is now more prevalently employed than surgical intervention as the therapeutic approach for PD.

18 October 2025 in Annals of Epidemiology
Verified
Journal Article
Closed access
AYA.M. Yeung
A.M. Yeung
MHM.T. Hukill
M.T. Hukill
JAJ.A. Alkalai
J.A. Alkalai
MKM.L. Keswa
M.L. Keswa
BTB.G. Teshome
B.G. Teshome
RGR.G. Glezer
R.G. Glezer